22- NCT043
48,435 A Randomized,
Double-Blind,
Placebo-Controlled
Clinical Trial to Determine the Safety and Efficacy of Hope
Biosciences
Allogeneic
Mesenchymal Stem
Cell Therapy (HBadMSCs) to Provide Protection Against COVID19 II Enrolling by invitation 100 AD-MSCs DOS: April 2020
DOC: April 2021 Both Child,
Adult, Older
Adult United States